Chapter Five - The FDA Stamp

CHAPTER FIVE

The FDA Stamp

IN THE PHARMACEUTICAL world, nothing matters more than the label.

It’s the sacred text. The legal shield, the marketing bible, and the rulebook for doctors and companies alike. And in 1995, Purdue got exactly what it needed.

Just one sentence.

Tucked inside the FDA-approved label for OxyContin was a line that would launch a thousand sales calls:

“Delayed absorption, as provided by OxyContin tablets, is believed to reduce the abuse liability of a drug.”

Believed.
Not proven. Not tested. Not backed by long-term data.
Just believed.

But belief was all Purdue needed.

That single sentence gave the sales team a golden ticket. It let them say truthfully and technically that the government had acknowledged Oxy was less addictive. Never mind that the word “believed” wasn’t a guarantee. Never mind that the FDA hadn’t studied long-term outcomes. Never mind that abuse rates were already starting to rise.

It was on the label.
That made it real.

The sentence was approved by an FDA official named Curtis Wright. He later left the agency, and in a move so brazen it would make a Wall Street banker blush, he went to work for Purdue.

It didn’t trigger alarms. It didn’t cause scandal.
Because at the time, nobody was looking.

The FDA, understaffed and under pressure, had little reason to block a slow-release opioid that sounded safer. Purdue framed it as innovation, not escalation. The agency signed off.

And just like that, OxyContin had federal legitimacy.

Doctors now had cover. Reps had ammo. Purdue had proof.

It was all above board, until it wasn’t.

As overdoses rose, the FDA tried to tighten regulations. But the horse was already out of the barn. Tens of millions of prescriptions had been written. Entire regions were addicted. And every effort to reassert control was met with industry lobbying, legal deflection, and more dead Americans.

The damage had been greenlit.

The FDA never meant to approve a weapon.
But it handed Purdue the trigger anyway.